<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102115</url>
  </required_header>
  <id_info>
    <org_study_id>LSCOR-001</org_study_id>
    <nct_id>NCT00102115</nct_id>
  </id_info>
  <brief_title>Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease</brief_title>
  <official_title>Phase 1 Dose Ranging Study to Evaluate Safety and Tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in Subjects With Advanced Age-Related Macular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Light Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Light Sciences LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium&#xD;
      (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1 study is a safety and tolerability investigation of LS11 photodynamic therapy in&#xD;
      subjects with persistent leaking neovascular membranes in patients with AMD who have a visual&#xD;
      acuity of 20/200 or less. This is a sequential group dose escalation trial with the cohorts&#xD;
      defined by increasing the light dose. Within each light-dose cohort, three (3) subjects will&#xD;
      be treated at a drug dose of 0.2 mg/kg or 0.5 mg/kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2004</start_date>
  <completion_date>January 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of leakage from choroidal neovascularization (CNV) of subjects with late stage AMD</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in visual performance</measure>
  </secondary_outcome>
  <enrollment>27</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50 or older&#xD;
&#xD;
          -  Subject is able to sign informed consent&#xD;
&#xD;
          -  Ability to complete 6 month trial&#xD;
&#xD;
          -  Present with advanced AMD and persistently leaking CNV&#xD;
&#xD;
          -  Adequate hematologic, renal and liver function&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Subject is able to safely undertake all protocol directed instructions&#xD;
&#xD;
          -  Visual acuity of 20/200 (logMAR 1.0)(6/60) or worse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant eye disease in eye to be treated&#xD;
&#xD;
          -  Prior ocular radionuclide treatments&#xD;
&#xD;
          -  Known allergic or hypersensitivity reactions to light and/or fluorescein and iodine or&#xD;
             shellfish&#xD;
&#xD;
          -  History of investigational drug or therapy including biologics within 30 days prior to&#xD;
             the study drug dosing&#xD;
&#xD;
          -  Women who are pregnant or lactating, or women of childbearing years not taking&#xD;
             adequate contraception precautions&#xD;
&#xD;
          -  History of porphyria, systemic lupus erythematosus, or xeroderma pigmentosum&#xD;
&#xD;
          -  History of clinically significant cardiovascular abnormalities, including myocardial&#xD;
             infarction in the past 6 months, uncontrolled arrhythmias, uncontrolled congestive&#xD;
             heart failure&#xD;
&#xD;
          -  Concomitant use of other drugs known to produce skin photosensitivity, e.g.&#xD;
             tetracycline, sulfonamides, phenothiazines, sulfonylureas, thiazide diuretics and&#xD;
             griseofulvin, St. John's Wort&#xD;
&#xD;
          -  Subjects with high or pathological myopia with an axial length &gt; 26mm or a refractive&#xD;
             error of &gt;/= -8.00D&#xD;
&#xD;
          -  Subjects with glaucoma and vision loss in either eye&#xD;
&#xD;
          -  Subject with a history of other choroidal leakage, e.g. histoplasmosis&#xD;
&#xD;
          -  Subjects with significant media opacity&#xD;
&#xD;
          -  Subjects diagnosed with diabetic retinopathy&#xD;
&#xD;
          -  Subjects who have had eye surgery within the past 3 months&#xD;
&#xD;
          -  Subjects who have received PDT treatment for AMD in the treatment eye&#xD;
&#xD;
          -  Any disease or condition that the sponsor or the investigator believes will impact the&#xD;
             subject's ability to adhere to the study schedule&#xD;
&#xD;
          -  Subjects participating in any concurrent trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Krasner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Light Sciences LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Retina</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lsoncology.com/</url>
    <description>Study sponsor</description>
  </link>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>January 21, 2005</study_first_submitted>
  <study_first_submitted_qc>January 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2005</study_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <keyword>Macular disease</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-Related Macular Disease</keyword>
  <keyword>PDT</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talaporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

